Carlos Adame

Statistics

Publications

Citations

756

H-Index

Active since

2017

Affiliations

University of California, Los Angeles(Current)

Carlos Adame is an author at University of California, Los Angeles specializing in oncology, cancer immunotherapy, and tyrosine kinase inhibitor therapy.

Publications per year

2017–2019

Publications

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman et al. · Journal of Thoracic Oncology · 2018 · 592 citations · Full text

Medicine, Oncology, Pharmacology +15

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Aaron Lisberg, D. Andrew Tucker, Jonathan W. Goldman et al. · Cancer Immunology Research · 2018 · 104 citations

Medicine, Oncology, Pharmacotherapy +16

Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer

Emily B. Tsai, Kelsey L. Pomykala, Kathleen Ruchalski et al. · Radiology · 2017 · 30 citations

Medicine, Oncology, Pathology +15

A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).

Arun S. Singh, Bartosz Chmielowski, J. Randolph Hecht et al. · Journal of Clinical Oncology · 2019 · 18 citations

Pharmacy, Oncology, Pharmacotherapy +17

A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST).

Arun S. Singh, Bartosz Chmielowski, J. Randolph Hecht et al. · Journal of Clinical Oncology · 2018 · 12 citations

Pharmacy, Oncology, Pharmacotherapy +17

1–5 of 5